Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Cannabis Dependence: early-phase trial registry

2 of 13 indexed Cannabis Dependence trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,315 of 28,707 conditions by registered trial count.

13 US clinical trials · 2 currently recruiting · #1,315 of 28,707 conditions by registered trial count

Cannabis Dependence: 13 US clinical trials tracked, 2 recruiting.

Cannabis Dependence is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute on Drug Abuse (NIDA), running 2 of these trials.

Enrollment posture brief

Registry condition cannabis-dependence

OPEN 2 | RECR 15% | LATE 2 | EARLY 4 | RANK #1315 | SPON 2

Nearest open-share peer: Arthroplasty, Replacement, Knee (15% recruiting · 13 trials)

ACL Injury61.5%Acute Biphenotypic Leukemia46.2%Accidental Falls30.8%Actinic Keratoses23.1%Cannabis Dependence (this)15%
Open-enrollment share among volume-matched conditions near Cannabis Dependence

Cannabis Dependence lists 2 open slots (15% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cannabis Dependence on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cannabis Dependence is recruiting below its size-band peers.

    2 of 13 indexed trials (15.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Cannabis Dependence research.

    National Institute on Drug Abuse (NIDA) accounts for 2 of 13 trials (15.4%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Most Cannabis Dependence trials plan to enrol fewer than 100 people.

    Median target enrolment is 70 among the 13 trials that report a genuine target (sentinel values excluded). 9 of those (69.2%) plan for fewer than 100 participants.

  4. Cannabis Dependence research is mostly interventional.

    10 interventional and 3 observational studies make up this index (76.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22Phase 42

Open and recent trials

13 total, page 1 of 1

RECRUITING 100 participants

Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Yale University

NCT01730781

RECRUITING NA 80 participants

Neuroimaging of Adolescent Cannabis Use Treatment

Indiana University

NCT07340554

ACTIVE NOT RECRUITING NA 10 participants

Breathwork-assisted Treatment for Cannabis Use Disorder

Elias Dakwar

NCT05219825

COMPLETED 822 participants

Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms

National Institute on Drug Abuse (NIDA)

NCT01603992

COMPLETED Phase 4 124 participants

Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine

Northwell Health

NCT01153490

COMPLETED 120 participants

Risk Perception in Drug-Dependent Adults With and Without Schizophrenia

National Institute on Drug Abuse (NIDA)

NCT01031563

COMPLETED Phase 2 70 participants

Treatment for Cannabis Withdrawal and Dependence

The Scripps Research Institute

NCT01611948

COMPLETED Phase 2 70 participants

Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal

Yale University

NCT01618656

COMPLETED Phase 1 68 participants

Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders

Louisiana State University and A&M College

NCT01875796

COMPLETED NA 35 participants

Neurobehavioral Measurement of Substance Users in Outpatient Treatment Setting

Hunter Holmes Mcguire Veteran Affairs Medical Center

NCT03662529

COMPLETED NA 33 participants

Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders

Dartmouth-Hitchcock Medical Center

NCT01834794

COMPLETED Phase 1 24 participants

An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents

Medical University of South Carolina

NCT00542750

COMPLETED Phase 4 11 participants

Reducing Cannabis Overuse With Prazosin

VA Puget Sound Health Care System

NCT04721353

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2
Phase 4 2

Named interventions

Most-linked intervention names on Cannabis Dependence records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
PF-04457845 Drug
1 trials
False Safety Behavior Elimination Therapy Behavioral
1 trials
Integrated Cannabis and Anxiety Reduction Treatment Behavioral
1 trials
Motivation Enhancement Therapy Behavioral
1 trials
Prazosin Hydrochloride Drug
1 trials
Manual-guided behavioral counseling Behavioral
1 trials
Treatment as usual therapy Behavioral
1 trials

US sites by state

Facility locations filed on Cannabis Dependence trials. A trial with sites in several states counts in each.

South Carolina 2 trials
New York 2 trials
Maryland 2 trials
Connecticut 2 trials
Washington 1 trials
Virginia 1 trials
New Hampshire 1 trials
Louisiana 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cannabis Dependence page

13 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cannabis Dependence condition card totals 13 registered trials; most-linked intervention Placebo; top US site state South Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.